Managing bipolar disorder or major depressive disorder during pregnancy requires careful consideration of treatment options, and for some individuals, lithium remains a vital component of their psychiatric care. This metallic element, when formulated as a pharmaceutical salt, crosses the placental barrier with relative ease, establishing a complex interplay between maternal therapeutic benefit and potential fetal exposure. Decisions surrounding its use are never made lightly, balancing the well-being of two patients simultaneously: the pregnant person and their developing baby.
How Lithium Works and Why It’s Used During Pregnancy
Lithium modulates neurotransmitter release and neuronal signaling in the brain, stabilizing mood fluctuations that can be debilitating. For individuals with severe bipolar disorder, discontinuing lithium often leads to a high risk of relapse, which can be more dangerous to both the person and the pregnancy than the medication itself. Untreated maternal mental illness is associated with significant risks, including poor prenatal care, substance use, and extreme stress, all of which can impact fetal development. Therefore, lithium is continued or initiated when the potential benefits for stabilizing the mother’s health clearly outweigh the potential risks to the fetus.
Potential Risks to the Developing Fetus
Cardiac Considerations
The most well-documented risk associated with first-trimester lithium exposure is an increased incidence of cardiac malformations, specifically a condition known as Ebstein’s anomaly. This defect affects the tricuspid valve, causing it to be malformed and positioned lower than normal in the heart. While the absolute risk is low, rising from a baseline of less than 1% in the general population to approximately 0.5–1% with lithium use, it remains a critical factor in prenatal counseling and decision-making.
Neonatal Adaptation Syndrome
Even when a pregnancy reaches full term without structural defects, exposure to lithium in the third trimester can lead to neonatal adaptation syndrome, also called neonatal toxicity. Because the drug is cleared from the fetus more slowly than the mother, newborns may exhibit symptoms such as lethargy, hypotonia, feeding difficulties, and respiratory distress shortly after birth. These symptoms are typically transient and managed in a hospital setting, but they underscore the importance of planning for delivery in a facility equipped for neonatal monitoring.
Monitoring and Dosing Strategies
Pregnant individuals taking lithium require a multidisciplinary approach involving psychiatrists, obstetricians, and maternal-fetal medicine specialists. Pharmacokinetic changes during pregnancy, particularly increased glomerular filtration rate in the first and second trimesters, often necessitate dosage increases to maintain therapeutic blood levels. Conversely, during delivery and postpartum, kidney function may shift again, requiring careful dose adjustments to prevent toxicity. Regular monitoring of serum lithium levels is essential to ensure they remain within the narrow therapeutic window.
